WGS

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

Retrieved on: 
木曜日, 5月 9, 2024
Public, Genetics, RC, Malaria, Health, Cardiology, WGS, KFSH, ANFAL, Organ transplantation, Conditional sentence, Life expectancy, Harmony, TPV, Harvard University

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care.

Key Points: 
  • RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care.
  • These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom.
  • KFSH&RC’s digital health initiatives extend to addressing broader health threats through technologies such as Whole Genomic Sequencing (WGS) and Advanced Radiation Therapy.
  • Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country's top ten most valuable brands.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
火曜日, 4月 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

Retrieved on: 
水曜日, 4月 24, 2024
TST, Genetically modified bacteria, WHO, Virtual reality, CDC, Multidrug-resistant tuberculosis, Bacteria, AMR, ESCMID, QIAGEN, ECCMID, MDR-TB, WGS, Doctor of Philosophy, Research, Workflow, Sputum, NGS, PCR, Disease, Patient, Panel, Mycobacterium tuberculosis, QGEN, Gold, Infection, D20, Emerging, Tuberculosis, Cerebrospinal fluid, Vaccine

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).

Key Points: 
  • The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).
  • By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
  • “The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN.
  • The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment.

GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset

Retrieved on: 
火曜日, 4月 23, 2024
Komodo, Congress, Partnership, WGS, Research, Life, Disease, GeneDx, Patient, Diagnosis, Standard of care, Clinical trial, Drug discovery, Medicine, Pharmaceutical industry

STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.

Key Points: 
  • STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.
  • The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment.
  • “The partnership between GeneDx and Komodo Health represents a milestone in advancing the understanding of rare disease and its associated drug development”, said Melanie Duquette, Chief Growth Officer, GeneDx.
  • GeneDx is continuing to showcase its value to biopharma companies through its participation in the World Orphan Drug Congress meeting in Boston, April 23-25th.

ProPhase Labs Unveils Project ZenQ-AI

Retrieved on: 
火曜日, 4月 16, 2024
Project, Cancer, Genomics, Whole genome sequencing, Safety, AI, Esophageal cancer, Nebula Genomics, Genetics, Machine learning, WGS, Doctor of Philosophy, DNA, SNP, Therapy, ADC, Marker beacon, Prophase, NVIDIA, Genome, EAC, Database, Diagnosis, CIO, Biomarker, Algorithm, Spacecraft, Medical device

Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual’s entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company’s BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.

Key Points: 
  • Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI.
  • "The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs.
  • To support the computational demands of Project ZenQ-AI, ProPhase Labs is utilizing a dual-approach in technology.
  • ProPhase Labs invites collaboration from across the scientific and medical communities to join in this groundbreaking initiative.

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

Retrieved on: 
木曜日, 4月 11, 2024
B-ALL, OGM, RNA, WGS, Genetic variation, Doctor of Philosophy, Research, Leukemia, Bone marrow, Biomarker, Genomics, Whole genome sequencing, Cancer, SVS, SAN, Vaccine

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.

Key Points: 
  • The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
  • The study concluded that OGM together with WGS can potentially identify new therapeutic targets and improve personalized medicine in pediatric leukemia and other cancers by providing a more complete view of genome variation, including structural variation.
  • The study findings showed that, of the 3,075 total SVs detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
  • The study also found that WGS detected 66 gene fusions, and that OGM was able to detect an additional 56 fusions that were missed by WGS.

Breakthrough whole genome report for embryos created during IVF delivers 100x data for parents, peer reviewed validation published

Retrieved on: 
月曜日, 4月 15, 2024
Risk, Pregnancy, Birth, WGS, Parent, IVF, Genetics, DNA, DSM-IV codes, Harvard Medical School, Genome, Multimedia, Molina Healthcare, Cancer, SAN, Interest, Vaccine

Orchid published its clinical validation of whole genome embryo screening, a step forward in IVF and genetic screening.

Key Points: 
  • Orchid published its clinical validation of whole genome embryo screening, a step forward in IVF and genetic screening.
  • Until now, standard genetic screening for embryos read less than 1% of an embryo's genome, which left most conditions undetected until pregnancy, birth, or even through childhood into adulthood.
  • Then, it could take years to accurately diagnose these conditions, causing harm, stress, and cost to impacted individuals and their families.
  • Now, Orchid have proven their ability to use whole-genome sequencing (WGS) to successfully read >99% of an embryo's genome, providing 100x more data than traditional tests.

NGS Strategies for Vaccine Development and Surveillance of Respiratory Viruses, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
月曜日, 4月 15, 2024
Public, Infection, Research and development, WGS, RNA, Doctor of Philosophy, Virus, Viral, NGS, Vaccine

TORONTO, April 15, 2024 /PRNewswire-PRWeb/ -- In the landscape of infectious diseases, next-generation sequencing (NGS) has emerged as a transformative technology, offering unparalleled insights into the complex dynamics of respiratory RNA viruses and critical gene sequences associated with viral infection. This webinar delves into the multifaceted applications of NGS, spanning from viral typing and targeted gene sequencing to whole-genome analysis, with a particular focus on its utility in outbreak tracing and clinical diagnostics.

Key Points: 
  • In this free webinar, discover cutting-edge advancements in next-generation sequencing (NGS) techniques tailored for analyzing respiratory RNA viruses, offering insights into viral diversity and evolution.
  • The featured speaker will discuss how NGS enhances vaccine development efforts by uncovering crucial information on viral diversity, evolution and potential vaccine targets essential for effective immunization strategies.
  • Register for this webinar today to gain insights into NGS sequencing techniques tailored for analyzing respiratory RNA viruses with a focus on vaccine development.
  • Join Kirthi Kumar Kutumbaka, PhD, Scientific Manager, Research & Development, Eurofins Viracor Biopharma Services , for the live webinar on Wednesday, May 1, 2024, at 11am EDT (4pm BST/UK).

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

Retrieved on: 
木曜日, 4月 4, 2024
WGS, GeneDx

STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.

Key Points: 
  • STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.
  • Management will host a conference call that day to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call are required to register online.
  • A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .

To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC Scientists Discover New Bacteria Species: Riyadhensis

Retrieved on: 
月曜日, 3月 25, 2024
WGS, Health, Disease, Education, Patient, Research, Hospital, Bacteria, Pseudomonas aeruginosa, RC, KFSH, Infection, Intensive care medicine, Newsweek, ICU, Vaccine

RIYADH, Saudi Arabia, March 25, 2024 (GLOBE NEWSWIRE) -- In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing (WGS) technology. This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies. Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.

Key Points: 
  • This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies.
  • Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.
  • This represents substantial progress in combating antibiotic resistance, developing pharmaceuticals, and preventing the spread of diseases.
  • Furthermore, this approach lays the groundwork for scientific collaboration at all levels, enhancing global efforts to combat antibiotic resistance.